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Background: The prevalence of ischemic heart disease is high. Few recent studies have investigated the periods
of sick leave of these patients. Our aim is to determine the length of sick leave after an acute coronary syndrome,
its costs, associated factors and to assess the use of antidepressants and/or anxiolytics.
Methods: An observational study of a retrospective cohort of patients on sick leave due to ischemic heart disease
in a health region between 2008–2011, with follow-up until the first return to work, death, or end of the study
(31/12/2012). Measurements: length of sick leave, sociodemographic variables and medical prescriptions.
Results: Four hundred and ninety-seven patients (mean age 53 years, 90.7% male), diagnosed with acute
myocardial infarction (60%), angina pectoris (20.7%) or chronic form of ischemic heart disease (19.1%). Thirty-seven
per cent of patients took anxiolytics the year after diagnosis and 15% took antidepressants. The average duration
of sick leave was 177 days (95% CI: 163–191 days). Patients diagnosed with acute myocardial infarction returned
to work after a mean of 192 days, compared to 128 days in cases with angina pectoris. Patients who took
antidepressants during the year after diagnosis returned to work after a mean of 240 days. The mean work
productivity loss was estimated to be 9,673 euros/person.
Conclusions: The mean duration of sick leave due to ischemic heart disease was almost six months. Consumption
of psychotropic medication doubled after the event. Older age, suffering an acute myocardial infarction and taking
antidepressants were associated with a longer sick leave period.
Keywords: Sick leave, Ischemic heart disease, Acute coronary syndrome, Coronary heart disease, Acute myocardial
ischemia, Cost, Anxiety/depressionBackground
In recent decades, mortality rates after Ischemic Heart
Disease (IHD) have declined in developed countries, but
IHD nonetheless remains the leading cause of death in
men and the second most frequent in women [1]. A
study in the primary care setting places the prevalence
of IHD in the general population over 15 years at 5.5%
[1]. The mortality rate of patients with Acute Coronary
Syndrome (ACS) in the first month is 50%; almost half
of these deaths occur in the first two hours, mainly due
to ventricular fibrillation [2]. This high prehospital* Correspondence: ncatala@hotmail.com
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hospital mortality has decreased notably [2].
It is estimated that every year cardiovascular disease
causes over 4 million deaths in Europe as a whole, and 1.9
million deaths in the European Union, most due to
Coronary Heart Disease [3]. From an epidemiological
point of view, IHD is particularly important in our envir-
onment due to its high prevalence, the high consumption
of resources it requires, and the associated mortality. The
increase in its prevalence and advances in technology have
established IHD as the disease with the greatest economic
impact in the developed countries [4]. Incapacity for work
is one of the indirect costs of the disease, but this issue
has not been widely studied [4–6]. Few authors have
assessed the length of periods of sick leave due to IHD
[2, 7–10] since the review of the topic conducted inle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Sicras-Mainar in 2009 quantified the cost per patient
following an episode of ACS at 14,069 euros (87% of
which were direct costs and 13% lost productivity
costs). The direct costs comprised primary care (20%)
and specialized care (67%), with hospitalization costs
accounting for 63% of the total [5].
Advances in the management of the acute phase of
ACS and of heart failure and revascularization in angina
pectoris, among other conditions, have improved prog-
nosis and recovery time. These developments may
potentially allow a much earlier return to work.
Incapacity for work is one of the major contributing
factors to the economic burden of a disease. If current
healthcare systems are to remain viable, clinicians, econ-
omists, health authorities and the biomedical industry
must work together to establish a consensus on issues
such assustainable periods of sick leave indifferent
clinical situations [4].
The present study was designed to determine the
mean length of sick leave after an ACS. We also aimed
to evaluate some of the associated factors such as age,
sex, specific diagnosis andthe prescription of medica-
tionfor depression or anxiety, and to estimate the indir-
ect costs of incapacity for work associated with ischemic
heart disease.
Methods
This observational, retrospective, longitudinal study ex-
amined data from the primary care clinical records of
patients in the health region of Lleida between 1 January
2008 and 31 December 2011. Data were extracted on all
patients aged between 18 and 65 years diagnosed with
IHD and on sick leave taken forthis condition. Patients’
evolution was followed until December 31, 2012.
Data source
The data were obtained from the medical histories in the
database of the Catalan Health Service primary care sec-
tion. In Catalonia, the use of the health card is mandatory
to obtain medication through the Social Security system.
The sedatives prescribed corresponded to the groups
N03AE/N05BA-BB-BX-CD-CF-CM and the antidepres-
sants to the groups N06A/N06B/N06C in the Anatomical
Therapeutic Chemical classification used in Spain [12].
Date of birth, sex, employment, exitus (if appropri-
ate) and diagnosis of IHD were extracted from the
primary care information systems in accordance with
the International Classification of Diseases-10 (ische-
mic heart disease: I20-I25).
Variables
The variables assessed were length of sick leave period
(calculated from the beginning of the leave until thereturn to work, or until 31/12/2012 or date of death),
age at the beginning of sick leave, sex, clinical diagnosis
of IHD, and the prescription of antidepressants and/or
anxiolytics.
Patient selection criteria
Patients with incapacity due to IHD recorded between 1
January 2008 and 31 December 2011, aged 18 to 65 at
the time of diagnosis, and living in the Lleida health re-
gion were included.
Non-healthcare costs
Indirect costs were those relating to productivity loss
(number of periods of sick leave and total days off
work). They were quantified according to the minimum
wage (Source: Spanish Institute of Statistics), consider-
ing the cost per day not worked at 54.65 euros [5].
Indirect costs were estimated for the whole of the pa-
tients’ follow-up period.
Statistical analysis
Descriptive analysis of the general characteristics of the
cohort, expressing qualitative variables as frequencies
and percentages and quantitative variables as means and
standard deviations (SD). The duration of sick leave was
estimated by survival analysis until the return to workus-
ing the Kaplan-Meier method. The length of periods of
sick leave was compared using the Log-Rank hypothesis
test. At multivariate level, Hazards ratios for return to
workwere estimated from the fit of the multivariate Cox
regression models. The assumption of proportional haz-
ards of the Cox models was evaluated using Schofield re-
siduals. Data were analysed using the IBM SPSS statistical
package (version 19). The main results are expressed with
95% confidence intervals (95%) and p-values less than 0.05
were considered statistically significant.
Results
Of a total of 497 patients with incapacity due to IHD,
90.7% were male. The most common diagnosis was
acute myocardial infarction (AMI - 59.4%), followed by
angina pectoris (20.7%) and chronic forms of IHD
(19.1%). The remaining 0.8% were due to other acute is-
chemic heart diseases and complications after AMI. The
average age was 53 years (SD: 7.4). Broken down by
years, 142 individuals were diagnosed with IHD (28.6%)
in 2008; 117 (23.5%) in 2009; 112 (22.5%) in 2010, and
finally 126 (25.4%) in 2011. Anxiolytic treatment was re-
quired by 37% of patients within 12 months of diagnosis,
and antidepressant treatment by 15% (Table 1).
The estimated mean length of sick leave was 177 days
(95% CI 163–191). In women it was 152 days compared
with 180 days in men, though the difference was not
Table 1 Descriptive data of the variables analysed
Variables Number Percent
Diagnostic code (CIE10) and description
Angina (I20) 103 20.70%
Acute myocardial infarct (AMI) (I21) 295 59.40%
Complications following AMI (I23) 1 0.20%
Other acute ischemic heart disease (I24) 3 0.60%
Chronic ischemic heart disease (I25) 95 19.10%
Age group
<=45 years 88 17.70%
46 to 55 195 39.20%
> = 56 214 43.10%
Year of sick leave
2008 142 28.60%
2009 117 23.50%
2010 112 22.50%
2011 126 25.40%
Sex
Female 48 9.70%
Male 449 90.30%
Medication dispensed : Yes/No ATC code)
Prior sedative (N03AE N05BA-BB-BX-CD-CF-CM)
Previous 136 27.4%
Previous 6 months 73 14.7%
Previous 12 months 95 19.1%
Subsequent 12 months 184 37.0%
Antidepressants GT = N06A / N06B / N06C
Previous 74 14.9%
Previous 6 months 30 6.0%
Previous 12 months 39 7.8%
Subsequent 12 months 76 15.3%
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were on sick leave for less than four months.
The length of the sick leave period increased with
age, as the older group (≥56 years) had a mean sick
leave of 186 days (≈6 months) compared with 140 days
(≈4.5 months) in the ≤45 year group (p <0.05)
(Table 2). Patients with angina pectoris were the first
to return to work (Fig. 1); on average, patients diag-
nosed with AMI and IHD returned to work 60 days
(p = 0.002). Finally, patients who required antidepres-
sant medication in the 12 months after diagnosis had
longer periods of sick leave (p <0.05) than those who
did not (Table 2).
Table 3 shows the multivariate analysis of the hazards
ratios for returning to work depending on the variables
analysed. Delayed return to work was associated withthe diagnosis of myocardial infarction, older age, and
taking antidepressant treatment.
In 12 of the 497 cases studied, the full sick leave
period was not recorded. In five cases this was because
of the finalization of the study on 31/12/2012; one pa-
tient moved to another centre, and six died.
The mean indirect cost due to loss of work productiv-
ity was estimated at 9,673 euros.
Discussion
Patients who take sick leave due to IHD are predomin-
antly male, and more than half havediagnoses of AMI.
As regards medication, more than a third of these pa-
tients take anxiolytic treatment a year after diagnosis,
and 15% antidepressants. In fact, patients’ consumption
of anxiolytics or antidepressants doubles after the car-
diovascular event. The mean period of sick leave is
177 days; the figure increases with age and in patients
diagnosed with AMI. Patients receiving antidepressants
have the longest mean period of sick leave (233 days).
Most patients on sick leave are male. Recent survey-
based studies in the US continue to show a predomin-
ance of males in heart disease in general and in AMI in
particular [13, 14]. Among the 40–59 year age group,
the prevalence is 3.3% in males and 1.8% in females [13].
No recent data are available on the prevalence of heart
disease in our country, but an indirect estimation can be
made using data from the population surveys carried out
by the National Institute of Statistics [13, 15]. In the last
two surveys, which referred explicitly to AMI, estimates
for each age group were well below those recorded in
the US population, although males predominated in this
country as well (0.64% in men vs. 0.15% in women in
the 45–54 year age group 1.84% in men and 1.28% in
women in the 55–64 year age group). In fact, ever since
the Framingham cohort’s study it has been acknowl-
edged that the incidence of coronary events increases
rapidly with age and those rates are lower in women
than in men [13, 16, 17].
Although little recent information on the length of
sick leave due to IHD is available in the literature, our
results are consistent with the few reports published to
date. Andrée et al. [18] reported that 2.2% of applica-
tions for sick leave conceded in Spain in 2009 were due
to cardiovascular disease, and that the sick leave period
lasted more than six months in 69.9% of these patients.
As that study did not differentiate according to type of
cardiovascular event, the results cannot be compared
directly with ours, since we focused specifically on ische-
mic heart disease. Lopez de la Iglesia reported that, in
most cases of IHD, return to work is possible within 90
to 180 days [2]. Other sources like the Spanish National
Social Security Institute (INSS) set the mean time for re-
turn to work after AMI at 90 days, ranging between 60
Table 2 Estimated time in days of the overall period of sick leave according to group
95% CI 95% CI p-value
Variable Mean (Upper limit - Lower limit) Median (Upper limit - Lower limit)
Global 177.3 (163.5- 191.0) 116 (98.6- 133.4)
Diagnostic code (CIE10) and description 0.002
Angina (I20) 127.8 (99.9- 155.6) 68 (46.6- 89.4)
Acute Myocardial Infarction (I21) 191.8 (174.1- 209.5) 131 (102.1- 159.9)
Other acute ischemic heart disease (I24) 143.0 (47.8- 238.2) 187 (0.0- 412.6)
Chronic ischemic heart disease (I25) 187.7 (154.5- 220.9) 137 (105.7- 168.3)
Age group (in years) 0.042
<=45 years 139.7 (110.2- 169.2) 88 (56.7- 119.3)
46 to 55 184.4 (161.7- 207.1) 125 (98.4- 151.6)
> = 56 186.1 (165.2- 207.1) 137 (103.4- 170.6)
Sex 0.221
Female 152.5 (110.7- 194.3) 99 (62.8- 135.2)
Male 179.9 (165.3- 194.5) 119 (101.0- 137.0)
Previous medication
Previous sedative (N03AE N05BA-BB-BX-CD-CF-CM) SI 189.6 (162.7- 216.6) 126 (80.3- 171.7) 0.35
No 172.4 (156.5- 188.4) 112 (93.5- 130.5)
Sedative in previous 12 months (N03AE N05BA-BB-BX-CD-CF-CM) Si 208.4 (173.8- 243.0) 160 (84.5- 235.5) 0.045
No 169.7 (154.9- 184.5) 111 (95.1- 126.9)
Previous antidepressants: GT = N06A/N06B/N06C Si 181.3 (146.5- 216.1) 137 (90.2- 183.8) 0.577
No 176.5 (161.5- 191.4) 111 (93.6- 128.4)
Antidepressants in previous 12 months : GT = N06A/N06B/N06C Si 228.9 (174.0- 283.8) 191 (105.3- 276.7) 0.022
No 172.8 (158.7- 186.9) 110 (92.7- 127.3)
Subsequent medication (12 months)
Sedatives Si 199.3 (175.6- 223.0) 150 (113.5- 186.5) 0.015
No 164.2 (147.5- 180.9) 103 (88.9- 117.1)
Antidepressants Si 240.2 (199.3- 281.1) 196 (133.0- 259.0) <0.001
No 165.9 (151.6- 180.2) 108 (93.1- 122.9)
Fig. 1 Probability of return to work in relation to the length of sick
leave period
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the event and the diagnosis, with 30 days for both an-
gina pectoris and old myocardial infarction [10]. Other
studies of sick leave in the general population report
longer periods and a wide variability, ranging from
189 days in the study by Jiménez [8] to 244 days in the
study by Gutiérrez Morlote [9] and to a mean of 255 days
in the Andalusia study protocol [7].
After an extensive review of the bibliography, Perk &
Alexanderson (2004) state that few articles of scientific
quality specifically discuss the duration of sick leave due
to coronary heart disease. Perk & Alexanderson say that
in Sweden a sick leave of at least three months is com-
mon after AMI [11, 19], and that in several European
countries and the US the median duration of sick leave
in this situation is 60 days [20]. The review concludes
that there is no evidence to support the differences in
the sick leave period from an international perspective
Table 3 Estimation of Hazard Ratio (HR) of return to work in relation to the variables analysed using the Cox regression model
Variable 95%CI
Category HR (Lower level - Upper level) p-value
Sex
Female 1.36 (1.00- 1.86) 0,051
Age in years 0.99 (0.97- 1.00) 0.025
Diagnosis (Ref: Chronic ischemic heart disease) <0.001
Angina (CIE10:I20) 1.49 (1.12- 1.98) 0.006
Acute myocardial infarct (CIE10:I21) 0.91 (0.71- 1.15) 0.421
Medication previous 12 month (Ref: None)
Sedative (N03AE N05BA-BB-BX-CD-CF-CM) 0.88 (1.08- 0.72) 0.217
Antidepressants GT = N06A / N06B / N06C 0.64 (0.84- 0.48) 0.002
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job positions, considerations such as age, motivation,
satisfaction with previous position, salary, trade, un-
employment rates, comorbidity, or even economic as-
pects - which in some studies have proved more
influential on return to work than clinical endpoints -
are involved in the decision [21–23]. Lastly, an import-
ant aspect to be considered is the timing of the return to
work. Levine et al. say that traditionally, there was a
wide timeframe for return to work after an acute coron-
ary event [9, 21, 24]; however, this recommendation is
now obsolete as it does not take into account the major
improvements in acute therapies, preventive treatments
and cardiac rehabilitation that have been achieved in re-
cent years. Modern guidelines, though not entirely clear,
have shortened this timeframe to 1–3 months [25].
The factor associated most clearly with longer sick
leave was the concomitant use of antidepressant treat-
ment. Previous studies have demonstrated the associ-
ation between ischemic heart disease and depression:
patients with cardiovascular disease are twice as likely to
develop depression [26], and depression increases car-
diovascular mortality and mortality due to any other
cause [27], besides being associated with poorer progno-
sis and quality of life [26]. Consequently, several studies
recommend that these patients should be screened for
depressive symptoms [26, 28, 29] and stress the possible
impact of depression on adherence to treatment [28]. It
would also be interesting to determine whether early
intervention to treat depression alters the evolution of
the illness [26, 29] and whether this strategy shortens
periods of sick leave in these patients.
Acute coronary syndrome has a high economic bur-
den. The indirect costs associated with lost productivity,
which according to a previous study represents only 13%
of the total cost per person [5], are estimated at 9,673.05
euros per period of sick leave. For reference, according
to the National Institute of Statistics, the Spanishminimum wage during the study period was 8,400 euros
in 2008 and 8,979.6 euros in 2011 [30]. The 9,673 euros
represent a 115 and a 108% of the minimum interprofe-
sional salary in spain in year 2008 and 2011 respectively.
Obviously, the direct costs must also be added to the
equation.
The limitations of our study are mainly to do with the
data collection, due to the possible loss of some prescrip-
tions of antidepressant or anxiolytic medication supplied
without a Social Security prescription orthrough other
subsidized health insurance systems in Spain such as
ISFAS and MUFACE. However we believe that the pa-
tients not covered by Social Security represent only a
small proportion of the total and do not create a selection
bias. We should also bear in mind that this is a descriptive
study of the duration of sick leave for IHD which did not
have access to other data that might influence the condi-
tion – for instance, cardiovascular or socioeconomic risk
factors, or other prognostic risk factors associated with
the disease such as inclusion in a rehabilitation program.
On the other hand we are unable to include information
on the severity of the event, which would have been very
interesting. The patient’s type of employment should also
be considered, in terms of the physical exertion required
and the degree of associated stress. We would also like to
have references from other diseases. Future studies should
compare the economic impact of sick leave due to differ-
ent pathologies using the same methodology (i.e., the
same follow-up, the same context, and so on). These and
other factors, in addition to the calculation of the total
cost per patient (direct and indirect), should be included
in future studies.
Conclusions
Patients on sick leave due to ischemic heart disease
spend an average of almost six months off work, a con-
siderably longer period than that recommended by the
Spanish Social Security system. This means that the
Català Tella et al. BMC Cardiovascular Disorders  (2017) 17:32 Page 6 of 7indirect health costs of acute coronary syndrome are
particularly high. Patients are mostly men, and the most
frequent diagnosis is AMI. After the event, patients’
consumption of medication doubles, with over a third
receiving anxiolytics and 15% antidepressants. The
factors associated with a longer duration of incapacity
are older age, acute myocardial infarction and receiving
antidepressant treatment.
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